Prognostic biomarker TSC2 in gastric cancer and its correlation with immune infiltration
10.3760/cma.j.cn115396-20241105-00340
- VernacularTitle:胃癌预后生物标志物 TSC2及其与免疫浸润的相关性分析
- Author:
Yawen CHEN
1
;
Yunhe GAO
;
Zhi QIAO
Author Information
1. 中国人民解放军总医院第一医学中心普通外科医学部，北京 100853
- Keywords:
Stomach neoplasms;
Gene expression;
Biological markers;
Prognosis;
Immunity
- From:
International Journal of Surgery
2025;52(1):51-57
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression of TSC2 in gastric cancer and its correlation with prognostic value and immune infiltration. Methods:Through Utilizing bioinformatics and experimental validation, analyzed RNA sequencing data from 624 gastric cancer patients in the TCGA-STAD dataset and the TCGA-GTEx-STAD dataset from the Cancer Genome Atlas (TCGA) database. Immunohistochemical (IHC) images of TSC2 expression in normal and gastric cancer tissues were obtained from the Human Protein Atlas (HPA). Evaluated the relationship between TSC2 expression and clinicopathological features, prognosis, immune infiltration, and immune subtypes in gastric cancer. Additionally, the expression of TSC2 in gastric cell lines was assessed by quantitative real-time PCR (qRT-PCR). Statistical analysis was conducted using SPSS 26.0 and R4.2.1 software. Results:TSC2 expression was significantly downregulated in gastric cancer tissues and cell lines compared to normal tissues. Lower expression of TSC2 correlated with worse overall survival, first progression, and progression-free survival in gastric cancer patients. TSC2 expression positively correlated with the infiltration levels of B cells, CD8 + T cells, CD4 + T cells, and macrophages, while it negatively correlated with the levels of NK cells and eosinophils. Functional enrichment analysis indicated that TSC2 was involved in pathways related to cell cycle regulation, protein transport, and immune response. TSC2 expression also associated with different immune subtypes within gastric cancer. Conclusions:TSC2 expression is downregulated in gastric cancer and is associated with poor prognosis and immune infiltration. TSC2 may act as a potential prognostic biomarker and a therapeutic target for gastric cancer.
